News and Trends 19 Sep 2022 GENFIT to acquire Versantis to expand liver disease portfolio …care, GENFIT intends to seek approval of these candidates via expedited regulatory pathways. VS-02 is a pre-clinical oral, small molecule drug candidate being developed for the chronic management of HE,… September 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 15 Nov 2017 Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them …a consortium working on multiple sclerosis and where it’s going now. Topas has its lead candidate in MS, which as Jessen describes, “is a very difficult disease [because] even the… November 15, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2023 Seven molecular glue startups looking to stick around in the biotech industry …Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates. The term molecular glue refers to a small molecule that sticks two… October 24, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 23 Nov 2023 The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy …acts as an undercover agent to release other immune cells in the TME, as they would usually have much more barriers to entry. CT-0508: Carisma’s encouraging candidate in addressing HER2+… November 23, 2023 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases …target-selective small molecule hit candidates for further development and commercialization. Sosei Heptares receives an upfront payment of $37 million on signing and is eligible to receive development and commercial milestones… December 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 27 Feb 2019 How to Make Cancer Drug Resistance Futile …stop the cancer cells from developing resistance, letting the cancer drug work for longer. To identify promising add-on candidates, the company uses a robotic setup to screen thousands of drug… February 27, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform …and GSK. In its latest partnership, the Danish Biotech will identify and advance potential drug candidates for Amgen, which will have exclusive rights to buy any successful program. The big… October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 3 Oct 2025 The biggest biotech funding rounds in September 2025 …D funding. According to the company, the proceeds will support the advancement of its portfolio of clinical and preclinical candidates, which are designed to precisely treat the drivers of complex… October 3, 2025 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2019 Cellestia Secures €18M to Develop First-in-Class Cancer Drug …end of last year. Cellestia’s drug candidate is currently being tested in a phase I trial in patients with blood cancers and solid tumors that have mutations in the Notch… December 18, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and… December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 Will BMS Take Over a Danish Biotech in a Massive €400M Deal? Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech… March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2020 Therachon Founders Spin Out New Rare Disease Biotech With €31M Investment …several others. Therachon’s lead candidate is a drug to boost bone growth in people born with the genetic condition achondroplasia. The company’s second candidate was a drug to help nutrient… January 8, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email